ADA Technologies to Develop Advanced Electrochemical Ultracapacitor Systems

ADA Technologies, Inc. received an $70,000 contract from the U.S. Army for Phase I research into the development of advanced electrochemical ultracapacitor systems for use in hybrid electronic vehicles (HEVs) for high power military applications.

ADA’s research will leverage its recent work funded by the National Science Foundation in which new low cost carbon nanotube (CNT) nanocomposite electrode materials were developed and proven in pouch-cell testing.

“ADA has considerable expertise in CNT nanotechnology. We expect the successful completion of this Phase I research to lead to development of ultracapacitors with the energy and power densities needed for military applications. In addition, these ultracapacitors will have safe operation over a wide temperature range and excellent cycle life, making them unique in the market,” said Douglas Campbell, ADA R&D program manager.

ADA’s work will be performed in partnership with San Diego, California based Maxwell Technologies, Inc., a commercial provider of ultracapacitors for HEV applications.

Source: http://www.adatech.com/

Citations

Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    ADA Technologies. (2019, February 12). ADA Technologies to Develop Advanced Electrochemical Ultracapacitor Systems. AZoNano. Retrieved on December 05, 2024 from https://www.azonano.com/news.aspx?newsID=21524.

  • MLA

    ADA Technologies. "ADA Technologies to Develop Advanced Electrochemical Ultracapacitor Systems". AZoNano. 05 December 2024. <https://www.azonano.com/news.aspx?newsID=21524>.

  • Chicago

    ADA Technologies. "ADA Technologies to Develop Advanced Electrochemical Ultracapacitor Systems". AZoNano. https://www.azonano.com/news.aspx?newsID=21524. (accessed December 05, 2024).

  • Harvard

    ADA Technologies. 2019. ADA Technologies to Develop Advanced Electrochemical Ultracapacitor Systems. AZoNano, viewed 05 December 2024, https://www.azonano.com/news.aspx?newsID=21524.

Tell Us What You Think

Do you have a review, update or anything you would like to add to this news story?

Leave your feedback
Your comment type
Submit

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.